Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
28.90
-0.65 (-2.20%)
Mar 10, 2026, 1:33 PM CST
-17.55%
Market Cap 2.27B
Revenue (ttm) 977.79M
Net Income (ttm) -102.95M
Shares Out 76.92M
EPS (ttm) -2.61
PE Ratio n/a
Forward PE n/a
Dividend 0.19 (0.71%)
Ex-Dividend Date Jul 24, 2025
Volume 763,694
Average Volume 175,553
Open 29.55
Previous Close 29.55
Day's Range 28.35 - 29.65
52-Week Range 23.50 - 35.20
Beta 0.51
RSI 72.97
Earnings Date Mar 20, 2026

About TPE:1762

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DMF or COS, and other API products. It also provides specialty API immunosuppressants, including mycophenolate mofetil, rapamycin, and tacrolimus; deriva... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1964
Employees 198
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1762
Full Company Profile

Financial Performance

In 2024, TPE:1762's revenue was 1.35 billion, a decrease of -35.42% compared to the previous year's 2.09 billion. Earnings were 53.03 million, a decrease of -79.98%.

Financial Statements

News

There is no news available yet.